Exogene
Exogene is a biotechnology company utilizing deep learning to develop TCR-based therapies for cancer, with a focus on eradicating solid tumors through its AI platform.
Company Overview
Exogene leverages deep learning technologies to discover innovative therapies targeting T-cell receptors (TCR) for cancer treatment. The company's primary focus is on developing TCR-based therapies aimed at eradicating solid tumors. By using its generative AI platform, Exogene can comprehensively mine the TCR sequence space to discover novel, high-affinity, and non-cross-reactive TCRs that are effective against targets common among various patients and tumor types.
Deep Learning for Cancer Therapy
Exogene specializes in utilizing deep learning to facilitate the discovery of TCR-based therapies. Through their advanced generative AI platform, the company can explore the vast TCR sequence space. This technology aids in identifying novel TCRs with high affinity and low cross-reactivity, which are crucial for targeting shared cancer antigens across different patients and tumor types. Such approaches hold promises for breakthroughs in treating solid tumors.
Research Collaboration with Immunocore
Exogene has initiated a research collaboration with Immunocore, a significant step towards enhancing its TCR discovery and development processes. This collaboration aims to use Exogene's AI-enabled platform to rapidly affinity-enhance TCRs. Leveraging AI's capability to refine and optimize TCR affinity can significantly bolster the effectiveness of cancer immunotherapies.
Media and Publications
Exogene has been spotlighted in various media outlets and publications, reflecting its influence in the field. They featured in the BioInnovator Spotlight podcast, where the company's foundation and aspirations for TCR-based cancer immunotherapies using AI were discussed. Additionally, they were highlighted in the Global Roundup for securing funding to support their TCR discovery initiatives. An article in Nature also discussed how artificial intelligence aids Exogene in T cell receptor screening for cell therapy discovery.
Key Partnerships
Exogene collaborates with a range of partners to advance its mission. These partners include Entrepreneur First, Creative Destruction Lab, R42 Group, The Francis Crick Institute, Selvedge Venture, and LifeArc. These partnerships provide strategic support, fostering innovation and progression in TCR-based cancer therapies.